Objective：To observe the clinical efficacy of autologous cytokine-induced killer cells（CIK） in the treatment of renal carcinoma. Methods：Totally 71 patients with renal carcinoma were randomly divided into treatment group（n=36） and control group（n=35）. Patients in treatment group and control group were received surgical resection first. Then patients in treatment group were treated with interleukin-2 and interferon treatment postoperatively and received CIK cell transfusion therapy at the end of treatment. Patients in control group only received interleukin-2 and interferon treatment. Immune function，quality of life，survival rate and adverse reactions were analyzed. Results：Ratios of CD3+，CD4+ and CD16+CD56+ were increased while those of CD8+ were decreased significantly after the treatment compared with those before the treatment in treatment group. There was no significant change before and after the treatment in ratios of CD3+，CD4+，CD4+/CD8+，CD16+ CD56+ and CD8+ in control group. Quality of life of 83.3% patients in the treatment group was improved while that of 57.1% patients in control group was improved，with statistical differences between two groups. One-year survival rates in treatment group and control group were 91.7% and 80.0%，one-year transfer rates in two groups were 13.9% and 22.9% and one-year recurrence rates in two groups were 5.6% and 11.4 %，respectively，without statistical differences between two groups. There was no statistical difference in side effects between treatment group and control group. Conclusions：CIK cells combined with surgical treatment can improve immune function and quality of life of patients with renal carcinoma.